These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27150087)

  • 21. Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies.
    Roopenian DC; Christianson GJ; Proetzel G; Sproule TJ
    Methods Mol Biol; 2016; 1438():103-14. PubMed ID: 27150086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption.
    Swiercz R; Mo M; Khare P; Schneider Z; Ober RJ; Ward ES
    Oncotarget; 2017 Jan; 8(2):3528-3541. PubMed ID: 27974681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn).
    Sand KM; Bern M; Nilsen J; Dalhus B; Gunnarsen KS; Cameron J; Grevys A; Bunting K; Sandlie I; Andersen JT
    J Biol Chem; 2014 Dec; 289(50):34583-94. PubMed ID: 25344603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative studies of the serum half-life extension of a protein via site-specific conjugation to a species-matched or -mismatched albumin.
    Yang B; Kim JC; Seong J; Tae G; Kwon I
    Biomater Sci; 2018 Jul; 6(8):2092-2100. PubMed ID: 29881837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Albumin and its application in drug delivery.
    Sleep D
    Expert Opin Drug Deliv; 2015 May; 12(5):793-812. PubMed ID: 25518870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An intact C-terminal end of albumin is required for its long half-life in humans.
    Nilsen J; Trabjerg E; Grevys A; Azevedo C; Brennan SO; Stensland M; Wilson J; Sand KMK; Bern M; Dalhus B; Roopenian DC; Sandlie I; Rand KD; Andersen JT
    Commun Biol; 2020 Apr; 3(1):181. PubMed ID: 32313072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multivalent Albumin-Neonatal Fc Receptor Interactions Mediate a Prominent Extension of the Serum Half-Life of a Therapeutic Protein.
    Yang B; Kwon I
    Mol Pharm; 2021 Jun; 18(6):2397-2405. PubMed ID: 33983743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
    Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
    Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new class of recombinant human albumin with multiple surface thiols exhibits stable conjugation and enhanced FcRn binding and blood circulation.
    Schelde KK; Nicholls K; Dagnæs-Hansen F; Bunting K; Rawsthorne H; Andersen B; Finnis CJA; Williamson M; Cameron J; Howard KA
    J Biol Chem; 2019 Mar; 294(10):3735-3743. PubMed ID: 30602565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fc engineering: serum half-life modulation through FcRn binding.
    Olafsen T
    Methods Mol Biol; 2012; 907():537-56. PubMed ID: 22907373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities.
    Tam SH; McCarthy SG; Brosnan K; Goldberg KM; Scallon BJ
    MAbs; 2013; 5(3):397-405. PubMed ID: 23549129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.
    Andersen JT; Pehrson R; Tolmachev V; Daba MB; Abrahmsén L; Ekblad C
    J Biol Chem; 2011 Feb; 286(7):5234-41. PubMed ID: 21138843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of intracellular neonatal Fc receptor-ligand interactions in primary macrophages using biophysical fluorescence techniques.
    Pannek A; Houghton FJ; Verhagen AM; Dower SK; Hinde E; Gleeson PA
    Mol Biol Cell; 2022 Jan; 33(1):ar6. PubMed ID: 34731029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human FcRn Tissue Expression Profile and Half-Life in PBMCs.
    Fan YY; Farrokhi V; Caiazzo T; Wang M; O'Hara DM; Neubert H
    Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31443181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data.
    Jones HM; Zhang Z; Jasper P; Luo H; Avery LB; King LE; Neubert H; Barton HA; Betts AM; Webster R
    CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):738-747. PubMed ID: 31464379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-like Peptide 1 Conjugated to Recombinant Human Serum Albumin Variants with Modified Neonatal Fc Receptor Binding Properties. Impact on Molecular Structure and Half-Life.
    Bukrinski JT; Sønderby P; Antunes F; Andersen B; Schmidt EGW; Peters GHJ; Harris P
    Biochemistry; 2017 Sep; 56(36):4860-4870. PubMed ID: 28799326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FcRn expression in cancer: Mechanistic basis and therapeutic opportunities.
    Rudnik-Jansen I; Howard KA
    J Control Release; 2021 Sep; 337():248-257. PubMed ID: 34245786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural basis of serum albumin recognition by SL335, an antibody Fab extending the serum half-life of protein therapeutics.
    Cho SY; Han J; Cha SH; Yoon SI
    Biochem Biophys Res Commun; 2020 Jun; 526(4):941-946. PubMed ID: 32284170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
    Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
    MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.